AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma - LARVOL DELTA

An Exploratory Clinical Study of Adebrelimab Combined with Apatinib and Chemotherapy as Neoadjuvant Therapy for Initially Unresectable Stage III Non-Small Cell Lung Cancer (ChiCTR) - P=N/A | N=52 | Not yet recruiting | Sponsor: Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital

New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD (clinicaltrials.gov) - P2 | N=44 | Not yet recruiting | Sponsor: Peking University Cancer Hospital & Institute

New P2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A single-arm, open-label clinical study of adebelimab in combination with apatinib mesylate and irinotecan in the treatment of advanced second-line esophageal cancer (ChiCTR) - P2 | N=32 | Recruiting | Sponsor: The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University

New P2 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Neoadjuvant Adebrelimab Combined with Chemotherapy and Apatinib for Initially Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase II, Open-Label, Single-Arm Exploratory Study (ELCC 2026) - No abstract available

Clinical • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Maintenance therapy with adebrelimab plus vunakizumab for ES-SCLC after first-line induction with adebrelimab and chemotherapy: a prospective, single-arm, phase II clinical study (ELCC 2026) - No abstract available

Clinical • P2 data • Lung Cancer • Small Cell Lung Cancer • Solid Tumor

Adebrelimab Combined with Definitive Concurrent Chemoradiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: A Single-Arm, Exploratory Phase II Study (ELCC 2026) - No abstract available

P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC): 5-year update of the phase 3 CAPSTONE-1 study (ELCC 2026) - No abstract available

Clinical • P3 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone (clinicaltrials.gov) - P2 | N=76 | Not yet recruiting | Sponsor: Peking University Cancer Hospital & Institute

New P2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Adebrelimab Neoadjuvant Treatment for Resectable ESCC (clinicaltrials.gov) - P=N/A | N=22 | Not yet recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital

New trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

SHR-8068-303: A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) (clinicaltrials.gov) - P3 | N=604 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Exploratory clinical study on preserving organs in patients with stage II-III non-small cell lung cancer(The Future Star) (ChiCTR) - P4 | N=598 | Recruiting | Sponsor: Jiangsu Cancer Hospital; Jiangsu Cancer Hospital

New P4 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • PD-L1

Trastuzumab rezetecan alone or in combination with adebrelimab in advanced solid tumors with HER2 expression or mutation: a prospective, multicenter, open, nonrandomized, multicohort study. (ChiCTR) - P=N/A | N=200 | Not yet recruiting | Sponsor: The Affiliated Hospital of Xuzhou Medical University; The Affiliated Hospital of Xuzhou Medical University

New trial • Solid Tumor • HER-2

NIOFA-02: A Randomized, Open-Label Cohort Study of Adebrelimab Combined with NALIRIFOX or Gemcitabine-Cisplatin (GC) as First-Line Treatment for Locally Advanced or Metastatic Biliary Tract Cancer (ChiCTR) - P4 | N=102 | Not yet recruiting | Sponsor: West China Hospital, Sichuan University; West China Hospital, Sichuan University

New P4 trial • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Gallbladder Cancer • Oncology • Solid Tumor

A Single-Arm, Exploratory Clinical Study of Irinotecan Liposome (II) in Combination with Adebrelimab for Platinum-Resistant Recurrent Ovarian Cancer (ChiCTR) - P=N/A | N=35 | Not yet recruiting | Sponsor: Renji Hospital Shanghai Jiao Tong University School of Medicine; Renji Hospital Shanghai Jiao Tong University School of Medicine

New trial • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

Disitamab Vedotin and Adebrelimab in combination with SOX in the perioperative treatment of HER2-expressing Locally Advanced Esophageal Adenocarcinoma and Esophagogastric Junction Adenocarcinoma: A Prospective, Single-Arm Phase II Study (ChiCTR) - P2 | N=39 | Not yet recruiting | Sponsor: Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences

New P2 trial • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2

A prospective clinical study on advanced or metastatic non-small cell lung cancer in the first-line treatment of adebelimab combined with emacetinib +/- chemotherapy (ChiCTR) - P4 | N=68 | Recruiting | Sponsor: Henan Cancer Hospital; Henan Cancer Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

HRS-4642-206: Phase IB/II clinical study of the safety, tolerability and efficacy of HRS-4642 in combination with other anti-tumor drugs in subjects with solid tumors (ChiCTR) - P1/2 | N=60 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital; Peking Union Medical College Hospital

New P1/2 trial • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • KRAS

Adebrelimab combined with irinotecan liposomal (ll), oxaliplatin, and 5-FU/LV conversion therapy for locally advanced pancreatic cancer: a prospective, single-arm, exploratory clinical study (ChiCTR) - P2 | N=47 | Recruiting | Sponsor: Jiangsu Provincial Hospital; Jiangsu Provincial Hospital

New P2 trial • Oncology • Pancreatic Cancer • Solid Tumor • CA 19-9

Exploratory Phase II Clinical Study of Adebrelimab Combined with Chemotherapy as Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma (ChiCTR) - P2 | N=44 | Not yet recruiting | Sponsor: Qilu Hospital of Shandong University; Qilu Hospital of Shandong University

New P2 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

SHR-1316-202: A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer (ChiCTR) - P2 | N=50 | Completed | Sponsor: Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center

New P2 trial • Cervical Cancer • Oncology • Solid Tumor

Exploratory Study of Adebrelimab Combined with GP Regimen as First-Line Therapy for Advanced Intrahepatic Cholangiocarcinoma (ChiCTR) - P2 | N=30 | Not yet recruiting | Sponsor: Eastern Theater Command General Hospital of the People's Liberation Army; Eastern Theater Command General Hospital of the People's Liberation Army

New P2 trial • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

A single-center, open-label, Phase II study of Adebrelimab Injection in combination with albumin-paclitaxel and cisplatin for neoadjuvant treatment of resectable oral squamous cell carcinoma (ChiCTR) - P2 | N=30 | Not yet recruiting | Sponsor: Hunan Cancer Hospital; Hunan Cancer Hospital

New P2 trial • Oncology • Oral Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Adbelimab combined with chemotherapy for perioperative treatment of resectable esophageal squamous cell carcinoma, exploring the representativeness of pathological responses in marking regional lymph nodes: A prospective, Phase II clinical stud (ChiCTR) - P2 | N=35 | Recruiting | Sponsor: Jiangsu Cancer Hospita; Jiangsu Cancer Hospita

New P2 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Prospective, Dual-Cohort, Phase II Study of PD-L1 Inhibitor Combined with Gemcitabine and Nab-Paclitaxel Followed by Sequential PD-L1 Inhibitor Combined with Irinotecan Liposome, Oxaliplatin, and 5-FU/LV for Conversion Therapy in Borderline Resectable/Locally Advanced Pancreatic Cancer (ChiCTR) - P2 | N=77 | Not yet recruiting | Sponsor: Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital Affiliated to Fudan University

New P2 trial • Oncology • Pancreatic Cancer • Solid Tumor

A prospective clinical study of Adebrelimab combined with chemotherapy and brain radiotherapy as the first-line treatment for extensive-stage small cell lung cancer with brain metastases (ChiCTR) - P4 | N=28 | Not yet recruiting | Sponsor: Henan Cancer Hospital; Henan Cancer Hospital

New P4 trial • Brain Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor